DAZOPRIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H23ClN4O2
Molecular Weight	326.822
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCN1CC(CN1CC)NC(=O)C2=CC(Cl)=C(N)C=C2OC

InChI

InChIKey=YFXIKEZOBJFVAQ-UHFFFAOYSA-N

InChI=1S/C15H23ClN4O2/c1-4-19-8-10(9-20(19)5-2)18-15(21)11-6-12(16)13(17)7-14(11)22-3/h6-7,10H,4-5,8-9,17H2,1-3H3,(H,18,21)

HIDE SMILES / InChI

Molecular Formula	C15H23ClN4O2
Molecular Weight	326.822
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2043916 | https://www.ncbi.nlm.nih.gov/pubmed/8453682

Dazopride is an antagonist of the 5-HT3 receptor and agonist of the 5-HT4 receptor, structurally related to metoclopramide. Dazopride was developed by A. H. Robins Company as an antiemetic and gastroprokinetic drug. Dazoptide demonstrated an antiemetic effect in the clinic after i.v. infusion to patients, receiving anticancer therapy.

Approval Year

Patents

Sample Use Guides

In Vivo Use Guide

i.v. infusions every 2 h beginning 30 min before the chemotherapy at doses 0.5 to 4.0 mg/kg.

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:04:18 GMT 2025` Edited by `admin` on `Mon Mar 31 18:04:18 GMT 2025`
Record UNII	CV07VSP2G8
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

4-AMINO-5-CHLORO-N-(1,2-DIETHYL-4-PYRAZOLIDINYL)-O-ANISAMIDE

Preferred Name

English

DAZOPRIDE

Official Name

English

dazopride [INN]

Common Name

English

Dazopride [WHO-DD]

Common Name

English

BENZAMIDE, 4-AMINO-5-CHLORO-N-(1,2-DIETHYL-4-PYRAZOLIDINYL)-2-METHOXY-

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C267